1. Korgavkar K., Xiong M., Weinstock M. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatology. 2013;149(11):1295 9. DOI:10.1001/jamadermatol.2013.5526.
2. Zwierzina H., Suciu S., Loeffler-Ragg J., et al. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia. 2005;19(11):1929 33. DOI:10.1038/sj.leu.2403934.
3. Keehn C.A., Belongie I.P., Shistik G., et al. The diagnosis, staging, and treatment options for mycosis fungoides. Cancer Control. 2007;14(2):102 11. DOI:10.1177/107327480701400203.
4. Cerroni L. Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018;37(1):2 10. DOI:10.12788/j.sder.2018.002.
5. Willemze R. Mycosis fungoides variants-clinicopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018;37(1):11 7. DOI:10.12788/j.sder.2018.004.
6. Olsen E., Vonderheid E., Pimpinelli N., et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) [Internet]. Vol. 110, Blood. Blood; 2007. p. 1713 22. DOI:10.1182/blood-2007-03-055749.
7. Horwitz S.M., Olsen E.A., Duvic M., et al. Review of the treatment of mycosis fungoides and Sézary syndrome: A stage-based approach [Internet]. Vol. 6, JNCCN Journal of the National Comprehensive Cancer Network. Jones and Bartlett Publishers; 2008. p. 436 42. DOI:10.6004/jnccn.2008.0033.
8. Delfau-Larue M.-H., Laroche L., Wechsler J., et al. Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma. Blood. 2000;96(9):2987 92. DOI:10.1182/blood.v96.9.2987.
9. Ponti R., Quaglino P., Novelli M., et al. T-cell receptor γ gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: Correlation with clinical, histological and i. Br J Dermatol. 2005;153(3):565 73. DOI:10.1111/j.1365-2133.2005.06649.x.
10. Kirsch I.R., Watanabe R., O’Malley J.T., et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med. 2015;7(308). DOI:10.1126/scitranslmed.aaa9122.
11. Matos T.R., de Rie M.A., Teunissen M.B.M. Research Techniques Made Simple: High-Throughput Sequencing of the T-Cell Receptor [Internet]. Vol. 137, Journal of Investigative Dermatology. Elsevier B.V.; 2017. p. e131 8. DOI:10.1016/j.jid.2017.04.001.
12. Scherer F., Kurtz D.M., Diehn M., et al. High-throughput sequencing for noninvasive disease detection in hematologic malignancies [Internet]. Vol. 130, Blood. American Society of Hematology; 2017. p. 440 52. DOI:10.1182/blood-2017-03-735639.
13. Jawed S.I., Myskowski P.L., Horwitz S., et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): Part I. Diagnosis: Clinical and histopathologic features and new molecular and biologic markers [Internet]. Vol. 70, Journal of the American Academy of Dermatology. Mosby Inc.; 2014. p. 205.e1-205.e16. DOI:10.1016/j.jaad.2013.07.049.
14. Rea B., Haun P., Emerson R., et al. Role of high-throughput sequencing in the diagnosis of cutaneous T-cell lymphoma. J Clin Pathol. 2018;71(9):814 20. DOI:10.1136/jclinpath-2018-205004.
15. Ferner R.E. Adverse drug reactions in dermatology [Internet]. Vol. 40, Clinical and Experimental Dermatology. Blackwell Publishing Ltd; 2015. p. 105 10. DOI:10.1111/ced.12572.
16. Federico M., Bellei M., Marcheselli L., et al. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. Br J Haematol. 2018;181(6):760 9. DOI:10.1111/bjh.15258.
17. Huang D.Y., Hu Y.F., Wei N., et al. Innovative analysis of predictors for overall survival from systemic non-Hodgkin T cell lymphoma using quantile regression analysis. Chin Med J (Engl). 2019;132(3):294 301. DOI:10.1097/CM9.0000000000000088.
18. Olsen E.A. Interferon in the treatment of cutaneous T-cell lymphoma [Internet]. Vol. 16, Dermatologic Therapy. Dermatol Ther; 2003. p. 311 21. DOI:10.1111/j.1396-0296.2003.01643.x.
19. Campbell J.M., Bateman E., Stephenson M.D., et al. Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Vol. 78, Cancer Chemotherapy and Pharmacology. Springer Verlag; 2016. p. 27 39. DOI:10.1007/s00280-016-3043-5.
20. Mann B.S., Johnson J.R., Cohen M.H., et al. FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T‐Cell Lymphoma. Oncologist. 2007;12(10):1247 52. DOI:10.1634/theoncologist.12-10-1247.
21. Prince H.M., Kim Y.H., Horwitz S., et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555 66. DOI:10.1016/S0140-6736(17)31266-7.
22. Gerami P., Guitart J. The spectrum of histopathologic and immunohistochemical findings in folliculotropic mycosis fungoides. Am J Surg Pathol. 2007;31(9):1430 8. DOI:10.1097/PAS.0b013e3180439bdc.
23. Alpdogan O., Kartan S., Johnson W., et al. Systemic therapy of cutaneous T-cell lymphoma (CTCL) [Internet]. Vol. 8, Chinese Clinical Oncology. AME Publishing Company; 2019. DOI:10.21037/cco.2019.01.02.
24. Swerdlow S.H., Campo E., Pileri S.A., et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016. DOI:10.1182/blood-2016-01-643569.